Logo image of IMA

IMAGENEBIO INC (IMA) Stock Fundamental Analysis

USA - NASDAQ:IMA - US45175G1085 - Common Stock

9.14 USD
-0.06 (-0.65%)
Last: 9/12/2025, 8:00:02 PM
7.86 USD
-1.28 (-14%)
After Hours: 9/5/2025, 8:22:30 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to IMA. IMA was compared to 195 industry peers in the Pharmaceuticals industry. IMA has a great financial health rating, but its profitability evaluates not so good. IMA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year IMA has reported negative net income.
IMA had a negative operating cash flow in the past year.
In the past 5 years IMA always reported negative net income.
IMA had a negative operating cash flow in each of the past 5 years.
IMA Yearly Net Income VS EBIT VS OCF VS FCFIMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M -60M -80M

1.2 Ratios

IMA's Return On Assets of -34.79% is in line compared to the rest of the industry. IMA outperforms 46.15% of its industry peers.
The Return On Equity of IMA (-39.10%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -34.79%
ROE -39.1%
ROIC N/A
ROA(3y)-36.73%
ROA(5y)-30.05%
ROE(3y)-42.01%
ROE(5y)-36.93%
ROIC(3y)N/A
ROIC(5y)N/A
IMA Yearly ROA, ROE, ROICIMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

IMA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMA Yearly Profit, Operating, Gross MarginsIMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

8

2. Health

2.1 Basic Checks

IMA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IMA remains at a similar level compared to 1 year ago.
The number of shares outstanding for IMA has been reduced compared to 5 years ago.
IMA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IMA Yearly Shares OutstandingIMA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
IMA Yearly Total Debt VS Total AssetsIMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of 0.40, we must say that IMA is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 0.40, IMA perfoms like the industry average, outperforming 55.38% of the companies in the same industry.
There is no outstanding debt for IMA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.4
ROIC/WACCN/A
WACC9.93%
IMA Yearly LT Debt VS Equity VS FCFIMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

IMA has a Current Ratio of 11.80. This indicates that IMA is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 11.80, IMA belongs to the best of the industry, outperforming 85.13% of the companies in the same industry.
A Quick Ratio of 11.80 indicates that IMA has no problem at all paying its short term obligations.
IMA has a better Quick ratio (11.80) than 85.13% of its industry peers.
Industry RankSector Rank
Current Ratio 11.8
Quick Ratio 11.8
IMA Yearly Current Assets VS Current LiabilitesIMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

0

3. Growth

3.1 Past

IMA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -121.62%.
IMA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-121.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-157.14%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -80.49% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-476%
EPS Next 2Y-114.48%
EPS Next 3Y-80.49%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMA Yearly Revenue VS EstimatesIMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 10M 20M 30M
IMA Yearly EPS VS EstimatesIMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IMA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMA Price Earnings VS Forward Price EarningsIMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMA Per share dataIMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A cheap valuation may be justified as IMA's earnings are expected to decrease with -80.49% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-114.48%
EPS Next 3Y-80.49%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IMA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMAGENEBIO INC

NASDAQ:IMA (9/12/2025, 8:00:02 PM)

After market: 7.86 -1.28 (-14%)

9.14

-0.06 (-0.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)07-24 2025-07-24/amc
Earnings (Next)11-05 2025-11-05/bmo
Inst Owners19.86%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner Change9.42%
Market Cap102.19M
Analysts80
Price Target281.52 (2980.09%)
Short Float %0.08%
Short Ratio0.67
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.51%
Min EPS beat(2)0.99%
Max EPS beat(2)22.03%
EPS beat(4)4
Avg EPS beat(4)16.01%
Min EPS beat(4)0.99%
Max EPS beat(4)22.03%
EPS beat(8)7
Avg EPS beat(8)11.1%
EPS beat(12)9
Avg EPS beat(12)6.9%
EPS beat(16)12
Avg EPS beat(16)-3.92%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-893.1%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.81
P/tB 0.81
EV/EBITDA N/A
EPS(TTM)-3.28
EYN/A
EPS(NY)-4.65
Fwd EYN/A
FCF(TTM)-4.11
FCFYN/A
OCF(TTM)-4.11
OCFYN/A
SpS0
BVpS11.26
TBVpS11.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.79%
ROE -39.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.73%
ROA(5y)-30.05%
ROE(3y)-42.01%
ROE(5y)-36.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.8
Quick Ratio 11.8
Altman-Z 0.4
F-Score3
WACC9.93%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-121.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-157.14%
EPS Next Y-476%
EPS Next 2Y-114.48%
EPS Next 3Y-80.49%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y27.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-66.37%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y42.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.31%
OCF growth 3YN/A
OCF growth 5YN/A